

Vaccines for Children (VFC) Program MenABCWY Vaccine Summary May 1, 2024

Purpose

Effective May 1, 2024, MenABCWY vaccine (Penbraya), manufactured by Pfizer is available to order through the Iowa VFC Program.

Food and Drug Administration (FDA)

On October 20, 2023 the FDA approved Pfizer's MenABCWY vaccine (Penbraya) for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. Penbraya is approved for use in individuals 10 through 25 years of age.

Full Morbidity and Mortality Weekly Report (MMWR): [Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023.](#)

On October 25, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) recommended Pfizer's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit. The ACIP recommendations for BENBRAYA have been adopted by the director of CDC.

VFC Resolution

The Federal VFC Program follows the ACIP recommendations for the use of MenABCWY vaccine as an option to vaccinate VFC eligible children ages 10 years through 18 years.

ACIP Recommended Schedule for MenABCWY Vaccine

MenABCWY vaccine may be used when both MenACWY and MenB vaccine are indicated at the same visit for:

- healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, and
- individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.

The licensed meningococcal B component vaccines are not interchangeable by manufacturer. The B component of the MenABCWY vaccine is MenB-FHbp (Trumenba). Administration of a B component vaccine (MenB or MenABCWY) requires that subsequent B component vaccine doses be from the same manufacturer. The minimum interval for Pfizer's MenABCWY vaccine is 6 months. Individuals at increased risk of meningococcal disease who are recommended to receive additional doses of MenACWY and MenB less than 6 months after a dose of pentavalent meningococcal vaccine should instead receive separate MenACWY and MenB-FHbp (Trumenba) vaccine.

[Recommended meningococcal vaccines for persons at increased risk for meningococcal disease due to serogroups A, B, C, W, or Y and who are due for both meningococcal A, C, W, and Y vaccine* and meningococcal B vaccine](#)

Recommended Dosage and Administration

- The recommended dose is 0.5mL administered as an intramuscular injection. It is supplied in kit that includes a vial of lyophilized MenACWY component (a sterile white powder), a prefilled syringe containing the MenB component and a vial adapter.
- MenABCWY is approved for use in individuals 10 through 25 years of age and is given as a two-dose series with a minimum interval of 6 months between doses.

Refer to the package inserts for further details. MenABCWY vaccine can be administered at the same time as other vaccines.

The Iowa HHS Immunization Program routinely follows and promotes the ACIP Recommended Immunization Schedule. The Immunization Program is implementing MenABCWY vaccine in accordance with the ACIP recommendations and the federal VFC Program resolution.

Vaccine Storage and Handling

Storage Before Reconstitution

- Store refrigerated at 2 - 8°C (36 - 46°F) in the original carton. During storage, a white deposit and clear supernatant may be observed in the prefilled syringe containing the MenB component. Store the carton horizontally to minimize the time necessary to resuspend the MenB component.
- Do not freeze.
- Do not use product if exposed to out of range temperatures.
- Do not use after expiration date shown on the label.

Storage After Reconstitution

- After reconstitution, administer immediately or store between 2°C and 30°C (36°F and 86°F) and use within 4 hours. Discard reconstituted vaccine if not used within 4 hours.

Precautions

- Moderate or severe acute illness with or without fever

Contraindications

- Severe allergic reaction (e.g. anaphylaxis) to any vaccine component or following a prior dose
- Severe allergic reaction to a tetanus toxoid-containing vaccine

Pregnancy and Breastfeeding

No data exist on the use of Penbraya during pregnancy or while breastfeeding. Limited data are available for MenB vaccination during pregnancy and vaccination with MenB should be deferred unless the pregnant person is at increased risk for acquiring meningococcal disease, and, after consultation with the healthcare provider, the benefits of vaccination are considered to outweigh the potential risks. When MenACWY is indicated, persons who are pregnant or breastfeeding should receive MenACWY-CRM or MenACWY-TT (MenQuadfi, Sanofi Pasteur).

Reporting of Adverse Events

Adverse events following administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online (<https://vaers.hhs.gov>).

CPT Code - 90623